S
MAZE

SignatureFD’s Maze Therapeutics MAZE Stock Holding History

SignatureFD’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507 Sell
17
-152
-90% -$3.98K ﹤0.01% 3357
2026
Q1 		$5.04K Buy
169
+155
+1,107% +$6.84K ﹤0.01% 2780
2025
Q4 		$580 Buy
+14
New +$481 ﹤0.01% 3215

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

SignatureFD's MAZE Position: Q2 2026 in Review

SignatureFD reduced its Maze Therapeutics (MAZE) stake by 90% in Q2 2026, selling an estimated $3.98K and leaving 17 shares worth $507. The position accounts for ﹤0.01% of the portfolio, ranked #3357.

SignatureFD first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.04K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • SignatureFD held 17 shares of Maze Therapeutics worth $507 as of Q2 2026.
  • SignatureFD sold 152 Maze Therapeutics shares in Q2 2026, an estimated $3.98K.
  • Maze Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3357 holding.
  • SignatureFD first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • SignatureFD's Maze Therapeutics position peaked at $5.04K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.